BMC Cancer最新文献

{"title":"Rectal prolapse as an initial presentation of colorectal cancer: a systematic review.","authors":"Fatemeh Shahabi, Abbas Abdollahi, Mahdieh Zarif-Sadeghian, Dorin Ziyaie, Ehsan Rahimpour, Majid Ansari, Esmat Davoudi-Monfared","doi":"10.1186/s12885-025-13924-4","DOIUrl":"10.1186/s12885-025-13924-4","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer rising incidence still pose a public health challenge. In the present systematic review, we aimed to study the colorectal cancer patients with initial presentation of rectal prolapse.</p><p><strong>Method: </strong>The study protocol was developed (PROSPERO CRD42017060473). We searched Web of Science, PubMed and Scopus to identify case reports of rectal Prolapse as a chief compliant of colorectal cancer. The Preferred Reporting Items for Systematic Reviews and Meta- Analysis (PRISMA) guidelines were used for screening and data extraction.</p><p><strong>Results: </strong>Thirty-one case reports were included in this review. More than half of the patients were females over 65 years old and mean ± SD age of the cases were 64 ± 17.9 years and, the female gender were mentioned in 17 (56%) case reports. The majority (64.5%) of the identified cancer belong to rectum and recto-sigmoid origin's location. In the history retained from the cases, rectal bleeding and constipation were the most frequent reported accompanied symptoms in colorectal cancer cases with initial presentation of rectal prolapse. 67.7% of all identified cases in this review published at 2015 and later.</p><p><strong>Conclusion: </strong>Rectal prolapse can be an initial presentation of colorectal cancer, which is more prevalent in female more than 65 years old. The most common symptoms accompanied rectal prolapse were rectal bleeding and constipation. According to rising published case reports on colorectal cancer patients with initial presentation of rectal prolapse in recent years, further work-up is recommended for patients without predisposing factors for a concomitant tumor.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"553"},"PeriodicalIF":3.4,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11948720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing prediction and stratifying risk: machine learning and bayesian-learning models for catheter-related thrombosis in chemotherapy patients.","authors":"Tao An, Han Han, Junying Xie, Yifan Wang, Yiqi Zhao, Hao Jia, Yanfeng Wang","doi":"10.1186/s12885-025-13946-y","DOIUrl":"10.1186/s12885-025-13946-y","url":null,"abstract":"<p><strong>Background: </strong>Catheter-related thrombosis (CRT) is a serious complication in cancer patients undergoing chemotherapy, yet existing risk prediction models demonstrate limited accuracy. This study aimed to evaluate the clinical utility of machine learning (ML) and Bayesian-learning models for CRT prediction in a large cohort of breast cancer patients undergoing catheterization.</p><p><strong>Methods: </strong>A total of 3337 breast cancer patients with central venous catheters (Cohort 1) were included to develop and test ML models. Given the suboptimal clinical feasibility of ML models, the Bayesian-learning model was constructed using odds ratio analysis and Gaussian distribution. The hazard ratio for the high-risk and low-risk groups was calculated using Cox proportional hazards regression analysis, and the model was validated in an independent cohort of 1274 patients (Cohort 2).</p><p><strong>Results: </strong>In Cohort 1, 246 patients (7.37%) developed CRT. Among the eight ML algorithms tested, WeightedEnsemble model exhibited relatively stable performance, achieving area under the receiver operating characteristic curves of 0.89 in the training set and 0.69 in the test set. WeightedEnsemble improved generalization by integrating multiple base models. The odds ratio analysis and Bayesian-learning modeling identified 4 independent risk factors: hemoglobin (threshold point [TP]: 134.63 g/L), activated partial thromboplastin time (TP: 31.71 s), total cholesterol (TP: 11.19 mmol/L), and catheterization approach (TP: peripherally inserted central catheters). A simplified risk stratification system was developed, categorizing patients into low-risk (0-1 factors) and high-risk (2-4 factors) groups. This system exhibited strong CRT risk discriminative ability, as confirmed through survival analysis (P < 0.001 in both cohorts). In Cohort 1, cox regression analysis showed that the high-risk group had hazard ratio (HR) of 1.60 (95% confidence interval [CI], 1.15-2.22) for both catheter indwelling time and catheter use duration. In Cohort 2, the system maintained stable discriminative ability, with an HR of 5.63 (95% CI, 3.46-9.21) for catheter indwelling time and 5.62 (95% CI, 3.46-9.12) for catheter use duration.</p><p><strong>Conclusions: </strong>While ML models demonstrated high predictive performance, their clinical applicability was limited due to complexity. The Bayesian-learning-based risk stratification model provided a simplified yet robust alternative, effectively predicting CRT risk and offering a clinically feasible tool for risk assessment in breast cancer patients with chemotherapy. Further validation in diverse cancer populations is warranted to refine its generalizability.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"552"},"PeriodicalIF":3.4,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11948715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143727968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RBMS1-HSPA8 axis activation drives head and neck squamous cell carcinoma progression.","authors":"Xinghong Yin, Meng Luo, Xiaojun Zha, Maoli Duan, Yehai Liu","doi":"10.1186/s12885-025-13937-z","DOIUrl":"10.1186/s12885-025-13937-z","url":null,"abstract":"<p><strong>Background: </strong>Head and Neck Squamous Cell Carcinoma (HNSCC) presents significant challenges in terms of treatment and prognosis, highlighting the urgent need for new therapeutic targets and the development of effective targeted therapies to enhance patient outcomes and survival.</p><p><strong>Methods: </strong>The expression level of RBMS1 in HNSCC was identified by GEO and TCGA databases through systematic bioinformatics analysis, and further verified in human specimens by quantitative Real-time PCR, Western blot, and immunohistochemistry. The results of CCK-8, colony formation assay, wound healing, Transwell, and tumor formation assays in nude mice showed that RBMS1 promoted the proliferation, migration, and invasion of HNSCC cells. The downstream target genes of RBMS1 were identified in the RBMS1 knockdown and the control groups of TU177 cells using RNA sequencing. HSPA8 was identified as a downstream target gene of RBMS1 in functional in vitro and tumor formation experiments in nude mice.</p><p><strong>Results: </strong>Elevated expression levels of RBMS1 in HNSCC were identified using relevant databases and validated in human specimens. In both in vitro and in vivo studies, overexpression of RBMS1 promoted the proliferation, migration, and invasion of HNSCC cells, whereas knockdown of RBMS1 significantly inhibited these processes. RNA sequencing analysis revealed HSPA8 as a downstream target of RBMS1, and rescue experiments confirmed that HSPA8 serves as a crucial intermediary in the regulatory pathway of tumor progression influenced by RBMS1.</p><p><strong>Conclusions: </strong>This study suggests that RBMS1 regulates HSPA8 to promote the proliferation, migration, and invasion of HNSCC cells, making it a potential therapeutic target for HNSCC.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"549"},"PeriodicalIF":3.4,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11948914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143718040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estrogen receptor α suppresses hepatocellular carcinoma by restricting M2 macrophage infiltration through the YAP-CCL2 axis.","authors":"De-Hua Wang, Dong-Wei He, Ting-Ting Lv, Xiao-Kuan Zhang, Zi-Jie Li, Zhi-Yu Wang","doi":"10.1186/s12885-025-13676-1","DOIUrl":"10.1186/s12885-025-13676-1","url":null,"abstract":"<p><strong>Purpose: </strong>Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, with significant differences in incidence and outcomes between men and women. Estrogen receptor alpha (ERα) expression is associated with sex-based differences and poor prognostic outcomes in HCC. However, the detailed function of ERα in the tumor microenvironment of HCC remains unclear.</p><p><strong>Methods: </strong>Bioinformatics analysis of differentially expressed genes in HCC samples was performed from publicly available databases, and ERα was selected. The function of ERα was examined in the cell experiments. A co-culture system was built to study function of ERα-treated liver cells on macrophages in vitro. The precise mechanism was determined using quantitative real-time PCR, western blotting, immunohistochemistry, mass spectrometry, co-immunoprecipitation, and dual-luciferase reporter assay.</p><p><strong>Results: </strong>ERα played an important role in the pathogenesis of sexual dimorphism in HCC. ERα mainly acted on macrophages in the tumor microenvironment (TME) of HCC and reduced M2 macrophage infiltration through CCL2. By acting on NF2 and 14-3-3theta, ERα enhanced YAP phosphorylation and attenuated the nuclear translocation of YAP, thereby suppressing CCL2 expression. It also acted as a transcription factor that regulated CCL2 expression at the transcriptional level.</p><p><strong>Conclusion: </strong>ERα/YAP/CCL2 signaling reduced M2 macrophages infiltration to inhibit HCC progression, revealing the effect of ERα in cancer cells on immune cells in HCC microenvironment.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"550"},"PeriodicalIF":3.4,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11948847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143727972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robotic single site versus robotic multiport hysterectomy in endometrial cancer: a systematic review and meta-analysis.","authors":"Weimin Xie, Zhangyi Wang, Xiaohang Liu, Songhong Tan","doi":"10.1186/s12885-025-13968-6","DOIUrl":"10.1186/s12885-025-13968-6","url":null,"abstract":"<p><strong>Objective: </strong>This meta-analysis aims to compare the safety and efficacy of robotic single-site hysterectomy (RSSH) with robotic multiport hysterectomy (RMPH) in treating endometrial cancer.</p><p><strong>Methods: </strong>We conducted a comprehensive literature search across several databases, including PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL), Embase, the Chinese National Knowledge Infrastructure (CNKI), Wan Fang, and the Chinese Science and Technology Journal Full Text Database (VIP). The search covered literature from inception until October 17, 2024. The primary outcomes included intraoperative complications, postoperative complications, postoperative pain scores, and satisfaction with cosmetic outcomes. The secondary outcomes included operative time (min), estimated blood loss (ml), hemoglobin drop, blood transfusion, conversion, postoperative hospital stay, lymph nodes harvested, sentinel lymph node identification, recurrence, and mortality during follow-up. Data analysis was performed using random-effects or fixed-effects models, calculating combined risk ratios (RR), weighted mean difference (WMD), and 95% confidence intervals (95% CI).</p><p><strong>Results: </strong>Five studies describing a total of 448 patients were retained and included for this meta-analysis. No significant differences were found between RSSH and RMPH regarding intraoperative complications, postoperative complications, and postoperative pain scores. There were also no differences in terms of operation time, estimated blood loss, hemoglobin drop, blood transfusion, conversion, postoperative hospital stay, lymph nodes harvested, and sentinel lymph node identification.</p><p><strong>Conclusion: </strong>This systematic review and meta-analysis provides evidence that RSSH is effective and safe for the treatment of endometrial cancer, as it is generally equivalent to RMPH regarding perioperative outcomes.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"554"},"PeriodicalIF":3.4,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complex interplay between type 2 diabetes mellitus and pancreatic cancer: insights from observational and mendelian randomization analyses.","authors":"Yuxin Wang, Lu Xie, Ye Gu, Hangbin Jin, Jianfeng Yang, Qiang Liu, Xiaofeng Zhang","doi":"10.1186/s12885-025-13976-6","DOIUrl":"10.1186/s12885-025-13976-6","url":null,"abstract":"<p><strong>Background: </strong>To investigate the causal relationship between type 2 diabetes mellitus (T2DM), pancreatic cancer (PC) risk and identify the mediating effects of various risk factors on that relationship.</p><p><strong>Methods: </strong>581 PC patients and 582 healthy controls who visited our center from January 2013 to December 2023 were included in this retrospective study. Multivariable logistic regression was performed to evaluate the association between T2DM and PC through odds ratios (ORs) and 95% confidence intervals (CIs). Mendelian randomization (MR) studies were then conducted to explore the causal relationship between T2DM and PC, and causal mediation analysis (CMA) to examine the mediating role of common risk factors.</p><p><strong>Results: </strong>After adjusting for confounding factors, retrospective analysis revealed significant association between new-onset diabetes mellitus (NODM) and PC risk, with insulin treatment also linked to increased PC development. The standard inverse-variance weighted (IVW) method indicated that genetic susceptibility to T2DM was associated with an increased risk of developing PC (OR = 1.11; 95% CI = 1.034-1.193). Furthermore, MR showed T2DM, insulin treatment, FGF-4, and sulfhydryl oxidase 2 may be independently associated with the prevalence of PC. Specially, CMA demonstrated that insulin treatment, FGF4, and sulfhydryl oxidase 2 mediate the pathway from T2DM to PC, contributing 56.8%, 55.8%, and 5.9% of the total effect, respectively.</p><p><strong>Conclusion: </strong>This study supports the association between T2DM, specifically NODM, and increased PC risk, with insulin therapy, FGF4, and sulfhydryl oxidase 2 mediating this pathway. Further research is required to elucidate the mechanisms underlying these mediating effects.</p><p><strong>Clinical trial number: </strong>not applicable.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"556"},"PeriodicalIF":3.4,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct 5-methylcytosine profiles of LncRNA in breast cancer brain metastasis.","authors":"Song Wang, Jianran Guo, Xinmiao Xian, Min Li, Anqi Zhang, Yujiao Liu, Yifei Zhang, Shen Chen, Guohao Gu, Xuehua Zhang, Dong Yan, Meng An, Li Pan, Bo Fu","doi":"10.1186/s12885-025-13948-w","DOIUrl":"10.1186/s12885-025-13948-w","url":null,"abstract":"<p><strong>Background: </strong>Recent studies have identified a complex relationship between methylation patterns and the development of various cancers. Breast cancer (BC) is the second leading cause of cancer mortality among women. Approximately 5-20% of BC patients are at risk of BC brain metastases (BCBM). Although 5-methylcytosine (m5C) has been identified as an important regulatory modifier, its distribution in BCBM is not well understood. This study aimed to investigate the distribution of m5C in BCBM.</p><p><strong>Materials and methods: </strong>Samples from BCBM (231-BR cells) and BC (MDA-MB-231 cells) groups were subjected to a comprehensive analysis of the m5C methylation in long non-coding RNA (lncRNA) using methylated RNA immunoprecipitation next-generation sequencing (MeRIP-seq). The expression levels of methylated genes in BC and adjacent tissues were verified through quantitative real-time polymerase chain reaction (RT-qPCR). Enrichment pathway analyses were through Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) to predict the potential functions of m5C in BCBM.</p><p><strong>Results: </strong>The MeRIP-seq analysis identified 23,934 m5C peaks in BCBM and 21,236 m5C in BC. A total of 9,480 annotated genes (BCBM) and 8,481 annotated genes (BC) were mapped. Notably, 1,819 methylation sites in lncRNA were upregulated in BCBM, whereas 2,415 methylation sites were upregulated in BC. Significant m5C hypermethylated lncRNAs included ENST00000477316, ENST00000478098 and uc002gtt.1, whereas hypomethylated lncRNAs included ENST00000600912, ENST00000493668, ENST00000544651 and ENST00000464989. These results were verified by qPCR and MeRIP-qPCR in BC and BCBM. Considering the strong association between m5C RNA methylation regulators and lncRNA, we examined the expression levels of 13 m5C RNA methylation regulators and observed significant differences between BC tissues and adjacent normal tissues. In addition, the interaction between regulators of altered expression and the differentially expressed genes in vitro was analyzed. The GO and KEGG pathways analyses revealed that genes significantly associated with m5C sites in lncRNA were linked to the BCBM signaling pathways.</p><p><strong>Conclusion: </strong>This uncovered significant variations in the levels and distribution of m5C in BCBM compared to BC. The findings provide a new theoretical understanding of the mechanisms of BCBM.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"557"},"PeriodicalIF":3.4,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of combined lifestyle and metabolic risks with cancer incidence in the UK biobank study.","authors":"Feng Lin, Wen Hu, Chenfenglin Yang, Binglin Cheng, Hongfan Chen, Jiaxin Li, Hanrui Zhu, Haixiang Zhang, Xiang Yuan, Xianyue Ren, Xiaohong Hong, Xinran Tang","doi":"10.1186/s12885-025-13955-x","DOIUrl":"10.1186/s12885-025-13955-x","url":null,"abstract":"<p><strong>Background: </strong>Although metabolic syndrome (MetS) is associated with an increased risk of various cancers, the combined impact of MetS and healthy lifestyle factors (HLF) on cancer risk is unclear. This study aimed to investigate the independent and combined effects of MetS and HLF on the risk of 16 site-specific cancers in a large community-based cohort.</p><p><strong>Methods: </strong>A total of 289,557 participants in the UK Biobank were analyzed. MetS was defined using a combination of metabolic factors, while HLF scores were evaluated based on lifestyle behaviors, such as smoking, alcohol consumption, physical activity, and diet. Cox proportional hazard models were used to investigate the relationship between MetS or HLF and cancer risk, adjusting for age, sex, ethnicity, education level, family history of cancer, and the Townsend Deprivation Index (TDI).</p><p><strong>Results: </strong>During a median follow-up of 11.69 years, 11,190 individuals developed cancer. MetS was associated with an increased risk of 9 cancers in men and 7 cancers in women. Compared with participants with unfavorable lifestyles, regardless of metabolic status, HLF was significantly associated with decreased risk of overall cancer (without MetS: HR: 0.812; 95% CI: 0.745-0.886 for intermediate lifestyle and HR: 0.757; 95% CI: 0.669-0.855 for favorable lifestyle; with MetS: HR: 0.702; 95% CI: 0.572-0.862 for favorable lifestyle) and oesophagus, stomach, liver, lung, bronchus, trachea cancers in men and of lung, bronchus, trachea cancers in women. Our analysis demonstrated that the protective association between HLF and reduced cancer risk was confined to subgroups without MetS. Specifically, this association was observed for cancers of the lip, oral cavity, pharynx, colon, rectum, pancreas, kidney, bladder, and lymphoid leukemia in men, and for overall cancer in women(HR: 0.917; 95% CI: 0.862-0.975 for intermediate lifestyle and HR: 0.875; 95% CI: 0.817-0.938 for favorable lifestyle).</p><p><strong>Conclusion: </strong>MetS elevates risks for multiple cancers, while adopting a healthy lifestyle reduces risks of oesophagus, stomach, and lung, bronchus, trachea cancers in men and lung, bronchus, trachea cancer in women, regardless of metabolic status. However, MetS counteracts lifestyle-mediated protection against specific cancers-including lip, oral cavity, pharynx, colon, rectum, pancreas, kidney, and bladder cancers in men, as well as pancreas and breast cancers in women. These findings underscore the necessity to develop metabolic status-stratified management strategies and implement proactive prevention of MetS.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"547"},"PeriodicalIF":3.4,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11948676/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143718011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"L-arginine dependence of breast cancer - molecular subtypes matter.","authors":"Juliane Hannemann, Leticia Oliveira-Ferrer, Anne Kathrin Goele, Yoana Mileva, Fiona Kleinsang, Antonia Röglin, Isabell Witzel, Volkmar Müller, Rainer Böger","doi":"10.1186/s12885-025-13908-4","DOIUrl":"10.1186/s12885-025-13908-4","url":null,"abstract":"<p><p>L-arginine limits proliferation in highly proliferative tissues. It is a substrate for nitric oxide synthases, arginases; its methylation by protein-L-arginine methyltransferases (PRMTs) leads to asymmetric (ADMA) and symmetric dimethylarginine (SDMA). We measured L-arginine and its metabolites L-ornithine, L-citrulline, ADMA, and SDMA in a prospective cohort of 243 women with primary breast cancer (BC) and their associations with mortality and disease recurrence during 88 (IQR, 82-93) months of follow-up. We quantified these metabolites and expression of genes involved in L-arginine metabolic pathways in MCF-7, BT-474, SK-BR-3, MDA-MB-231, and MDA-MB-468 cells representing ER-positive, HER2-positive, and triple-negative BC compared to MCF-12 A cells. Plasma L-arginine and ADMA concentrations were elevated in 47 patients with recurrent disease and in 34 non-survivors. ADMA was significantly associated with mortality and recurrent disease in Luminal A patients; low L-citrulline was significantly associated with survival in triple-negative BC. In all BC cells except MCF-7, DDAH1 and DDAH2 expression was higher than in MCF-12 A (DDAH1: 32-44 fold, DDAH2: 1.7-4.2 fold; p < 0.05). By contrast, MCF-7 cells showed low DDAH1 and DDAH2, but high PRMT4 and PRMT6 expression and high L-arginine content. BT-474 and MDA-MB-468 cells showed high ARG2 expression and high L-ornithine concentrations, and MDA-MB-468 cells had the highest L-citrulline/L-arginine ratio. In conclusion, regulation of L-arginine metabolic pathways shows a complex and differential pattern between BC subtypes. ADMA is a prognostic biomarker in Luminal A patients; its metabolizing enzyme, DDAH, is highly overexpressed in BC cells. Thus, fingerprinting of L-arginine metabolism may offer novel personalized treatment options within BC subtypes.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"546"},"PeriodicalIF":3.4,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11948839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143718029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proficient surgeons enhance conversion rates and sphincter preservation in robotic rectal cancer surgery with comparable long-term outcomes: a comparative study with laparoscopy in a large-volume center in China.","authors":"Xiaojie Wang, Yangyang Wang, Zhifen Chen, Zhifang Zheng, Shenghui Huang, Yanwu Sun, Ying Huang, Pan Chi","doi":"10.1186/s12885-024-13407-y","DOIUrl":"10.1186/s12885-024-13407-y","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Despite theoretical advantages, skepticism persists about robotic rectal cancer surgery due to the lack of evidence of benefit. This study aims to compare oncological and functional results of robotic-assisted surgery to laparoscopy, focusing on proficient surgeons with expertise in both techniques.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This retrospective study reviewed and compared 1304 patients who underwent either robotic surgery (n = 295) or laparoscopic surgery (n = 1009) for rectal cancer. The surgical procedures were performed by a team of highly skilled surgeons who individually carry out more than 350 laparoscopic or robotic colorectal cancer surgeries over the course of their career. Perioperative outcomes, recurrence data, and intestinal function outcomes were compared between groups with a propensity score matching (PSM) method. The primary outcomes were sphincter preservation and conversion to open laparotomy. Secondary endpoints included 3-year disease-free survival (DFS), 3-year overall survival (OS), complications, and the occurrence of low anterior resection syndrome (LARS). Fisher's exact test and χ2 were used to compare discrete variables between groups, while parametric (t-test) and nonparametric (U test, Kruskal-Wallis) tests were used for continuous outcomes, as appropriate. The Kaplan-Meier and log-rank tests were employed to analyze and compare the DFS and OS outcomes.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The patients in the robotic group were younger, with a higher cN stage, positive EMVI and CRM, and a lower tumor location compared to the patients in the laparoscopic group. The robotic group also had more neoadjuvant chemoradiotherapy, causing an imbalance in (y)pT and (y)pN stage. Following PSM, all covariates were effectively balanced between the two groups. The robotic group had significantly higher sphincter preservation rates (94.0% vs. 84.4%, P &lt; 0.001) and no conversions to open laparotomy, while the laparoscopic group had 7 cases (0 vs. 2.5%, P = 0.015). There were no significant differences observed in diverting ileostomy, operative time, estimated blood loss, complications, margin involvement, or duration of hospitalization. The median follow-up was 31 months. No significant differences were found between the robotic and laparoscopic groups in terms of 3-year OS (94.1% vs. 93.3%, P = 0.812) and DFS (85.9% vs. 84.7%, P = 0.797). The robotic group had similar rates of recurrence in various sites, including local, liver, lung, bone, and peritoneal metastases. Major LARS occurred in 11.3% of patients, while minor LARS occurred in 14.8% with no significant differences between the groups (P = 0.54).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Comparable complication rates, 3-year OS, and DFS were found between robotic and laparoscopic rectal cancer surgery. Furthermore, it shed light on supplementary benefits associated with this approach, such as decreased conversion rates and enhanced sphincter preserva","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"545"},"PeriodicalIF":3.4,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11948655/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143718032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}